The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Sanofi Deal Breathes New Life Into NVAX Stock Beginning next year, Sanofi will gain rights to co-market Novavax’s COVID-19 vaccine globally, except in certain countries where the company has ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Sanofi and GlaxoSmithKline said Oct. 28 that they will provide 200 million doses of their COVID-19 vaccine to the World Health Organization's Covax initiative if the vaccine receives regulatory ...

Sanofi and GlaxoSmithKline are working together to create a COVID-19 vaccine with funding from HHS, the drugmakers said April 14. The drugmakers said they will combine technology Sanofi has used ...

Drugmakers are racing to develop what would be a lucrative prize, but have sought financial support to mitigate the risks. Sanofi is working on two vaccine projects against COVID-19.

LONDON (AP) — Drugmakers Sanofi and GlaxoSmithKline said Friday that their potential COVID-19 vaccine won’t be ready until late next year because they need to improve the shot’s ...